Researches and develops medicines for various therapeutic areas. Launches independent 'Vants' focused on specific diseases or technologies. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 38% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $8.3M a year. A small number, but proof the product has real buyers.
There is $4.3B in the vault; even if every debt were paid off, $4.2B would remain.
A loss of $299.8M against $8.3M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 22/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 33/100.
On our five-subject report card, ROIV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ROIV is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.